JNCCN 研究:B-ALL 患儿家庭在治疗全程承受显著经济与家庭负担
Even highly curable childhood cancers can take a substantial toll on families
一项基于儿童肿瘤协作组(COG)AALL0932 试验的多中心研究发现,420 名标准风险 B 细胞急性淋巴细胞白血病(B-ALL)患儿的家庭从确诊早期起就持续面临就业、婚姻等家庭变化。
该研究将家庭负担纳入儿童白血病治疗评估,显示负担在确诊后早期即出现并持续全程,提示照护中应同步考虑家庭支持。
New research in the Journal of the National Comprehensive Cancer Network finds that families of children receiving treatment for B-cell acute lymphoblastic leukemia (B-ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a new multicenter study embedded in a Children's Oncology Group (COG) trial. The COG includes more than 200 member institutions that treat about 80% of all new cases of childhood and adolescent cancer; therefore, these findings represent the experiences of most families.
The study followed family outcomes over time in 420 children being treated for standard-risk B-ALL, from September 2010 through April 2013. B-ALL is the most common childhood cancer, with treatment typically lasting about 2.5 years.
Investigators found that adverse family outcomes developed quickly and remained common throughout the entire duration of therapy, including household employment changes or changes in marital status. Among randomized participants, 56.2% of families reported at least one household change within approximately two months of diagnosis, increasing to 81.2% by 26 months.
"As providers, we should always be thinking about how to minimize the secondary impacts of cancer therapy," said lead author Rozalyn L. Rodwin, M.D., M.H.S., of Yale Cancer Center/Smilow Cancer Hospital.
"These findings highlight how cancer therapy can impact a child's family financially, socially and emotionally. Families are impacted early and continue to be impacted; therefore, support must be considered as part of cancer care from day one."
The trial also compared family outcomes between those groups receiving maintenance vincristine/dexamethasone given every four weeks (VCR/DEX4) versus every 12 weeks (VCR/DEX12). Families in the VCR/DEX12 group were less likely to report at least $100 in leukemia-related expenses after randomization, but most other family outcomes were similar between treatment groups.
"We had hoped this study would find that reduced treatment intensity led to reduced adverse family outcomes, but for the most part that wasn't the case. This highlights the need for family support regardless of treatment intensity," noted Rodwin.
"I think that as providers, we should routinely screen caregivers for financial toxicity and also make sure to ask about unexpected employment changes and other changes in the home so that families can be directed to appropriate resources."
"This study highlights critical findings that despite incredible improvements in survival for childhood B-ALL, the burden from treatment is still a really big deal," commented Melissa Acquazzino, M.D., M.S., of Fred & Pamela Buffett Cancer Center, who was not involved with this research.
Acquazzino, who is also a member of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) panels for Pediatric Aggressive Mature B-Cell Lymphomas and Adolescent and Young Adult (AYA) Oncology, continued, "Significant financial hardship and family distress can develop early on in treatment and remain throughout, negatively impacting the child's physical and emotional health. Ongoing research and investment in multidisciplinary teams are needed to improve the experience and decrease any burden placed on our patients' families."
More information
Adverse Family Outcomes in Children With B-Cell Acute Lymphoblastic Leukemia From the Multicenter Trial Children's Oncology Group AALL0932, Journal of the National Comprehensive Cancer Network (2026). DOI: 10.6004/jnccn.2026.7048
Provided by National Comprehensive Cancer Network
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Even highly curable childhood cancers can take a substantial toll on families (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-highly-curable-childhood-cancers-substantial.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com